ASH 2023 | Ex vivo expanded NK cells for hematological cancer immunotherapy
Meral Beksac, MD, PhD, Istinye University Ankara Liv Hospital, Ankara, Turkey, explores the use of natural killer (NK) cells in treating patients with hematological cancers and solid tumors. NK cells, sourced from peripheral or cord blood, can be expanded in vitro and infused into the patient to offer immune defense against cancer cells. Their potential can be harnessed in CAR-NK constructs and combination with enhancing molecules, like AFM13, further amplify their activity. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: BMS, Takeda, Amgen; Advisory Board: Pfizer, Menarini, Janssen; Speakers Bureau: Janssen.
